Abstract:Cancer is a leading cause of death worldwide, resulting in ∼10 million deaths in 2020. Major oncogenic effectors are the Myc proto-oncogene family, which consists of three members including c-Myc, N-Myc, and L-Myc. As a pertinent example of the role of the Myc family in tumorigenesis, amplification of MYCN in childhood neuroblastoma strongly correlates with poor patient prognosis. Complexes between Myc oncoproteins and their partners such as hypoxia-inducible factor-1α and Myc-associated protein X (MAX) result in proliferation arrest and pro-proliferative effects, respectively. Interactions with other proteins are also important for N-Myc activity. For instance, the enhancer of zest homolog 2 (EZH2) binds directly to N-Myc to stabilize it by acting as a competitor against the ubiquitin ligase, SCFFBXW7, which prevents proteasomal degradation. Heat shock protein 90 may also be involved in N-Myc stabilization since it binds to EZH2 and prevents its degradation. N-Myc downstream-regulated gene 1 (NDRG1) is downregulated by N-Myc and participates in the regulation of cellular proliferation via associating with other proteins, such as glycogen synthase kinase-3β and low-density lipoprotein receptor-related protein 6. These molecular interactions provide a better understanding of the biologic roles of N-Myc and NDRG1, which can be potentially used as therapeutic targets. In addition to directly targeting these proteins, disrupting their key interactions may also be a promising strategy for anti-cancer drug development. This review examines the interactions between the Myc proteins and other molecules, with a special focus on the relationship between N-Myc and NDRG1 and possible therapeutic interventions. SIGNIFICANCE STATEMENT: Neuroblastoma is one of the most common childhood solid tumors, with a dismal five-year survival rate. This problem makes it imperative to discover new and more effective therapeutics. The molecular interactions between major oncogenic drivers of the Myc family and other key proteins; for example, the metastasis suppressor, NDRG1, may potentially be used as targets for anti-neuroblastoma drug development. In addition to directly targeting these proteins, disrupting their key molecular interactions may also be promising for drug discovery.

A review of nuclear Dbf2-related kinase 1 (NDR1) protein interaction as promising new target for cancer therapy

Targeting ribonucleotide reductase for cancer therapy.

NDR2 is Critical for the Osteoclastogenesis by Regulating ULK1-mediated Mitophagy.

Discovery of a small-molecule NDR1 agonist for prostate cancer therapy

Targeting neuropilin-1 interactions is a promising anti-tumor strategy

The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics

The Role of DDR1 in Cancer and the Progress of Its Selective Inhibitors

Development and therapeutic potential of DNA-dependent protein kinase inhibitors

N-myc Downstream Regulated Gene 1 Inhibition of Tumor Progression in Caco2 Cells.

NDR1/FBXO11 promotes phosphorylation-mediated ubiquitination of β-catenin to suppress metastasis in prostate cancer

DDR1-targeted therapies: current limitations and future potential

Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.

Targeting Pin1 for Modulation of Cell Motility and Cancer Therapy

NDR1/STK38 potentiates NF-κB activation by its kinase activity.

Proteomics Analysis of the Interactome of N-myc Downstream Regulated Gene 1 and Its Interactions with the Androgen Response Program in Prostate Cancer Cells

The actin-binding protein drebrin disrupts NF2-LATS kinases complex assembly to facilitate liver tumorigenesis

Discoidin Domain Receptor 1 As a Potent Therapeutic Target in Solid Tumors

Oncogenic Functions of Protein Kinase D2 and D3 in Regulating Multiple Cancer-Related Pathways in Breast Cancer

The many substrates and functions of NEDD4-1

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Nuclear Dbf2-related Kinase 1 functions as tumor suppressor in glioblastoma by phosphorylation of Yes-associated protein